Results 21 to 30 of about 25,586 (182)

Integration of three machine learning algorithms identifies characteristic RNA binding proteins linked with diagnosis, immunity and pyroptosis of IgA nephropathy

Frontiers in Genetics, 2022
Objective: RNA-binding proteins (RBPs) are essential for most post-transcriptional regulatory events, which exert critical roles in nearly all aspects of cell biology.
Xueqin Zhang, Peng Chao, Hong Jiang, Shufen Yang, Gulimire Muhetaer, Jun Zhang, Xue Song, Chen Lu   +7 more
doaj   +1 more source

Aspirin alleviates the symptoms of immunoglobulin A nephropathy via suppressing platelets-mediated non-canonical NF-κB activation in B cells

STEMedicine, 2023
Purpose: Antiplatelet aggregation drugs, such as aspirin, can alleviate pathological renal damage in immunoglobulin A (IgA) nephropathy, although the precise mechanism is unclear.
Nomvula Johannes, Priyanka Maunga
doaj   +1 more source

IgA Glycosylation in IgA Nephropathy [PDF]

, 1998
IgA nephropathy (IgAN) is the commonest form of glomerulonephritis in developed countries where renal biopsy is widely practiced1. IgAN is defined by the deposition of IgA in the glomerular mesangium. Most typically, patients present with episodes of visible haematuria, which often concide with respiratory or gastrointestinal infection.
A, Allen, J, Feehally
openaire   +2 more sources

IgA nephropathy enigma [PDF]

Clinical Immunology, 2016
IgA nephropathy (IgAN) is the leading cause of primary glomerulonephritis in the world. The disease is characterized by the presence of IgA-containing immune complexes in the circulation and in mesangial deposits with ensuing glomerular injury. Although in humans there are two IgA subclasses, only IgA1 molecules are involved.
Jiri, Mestecky, Jan, Novak, Zina, Moldoveanu, Milan, Raska   +3 more
openaire   +2 more sources

Use of gas chromatography mass spectrometry to elucidate metabolites predicting the phenotypes of IgA nephropathy in hyper IgA mice.

PLoS ONE, 2019
IgA nephropathy, a common chronic kidney disease, has various possible outcomes. Therefore, the identification of novel prognostic biomarkers is needed.
Makoto Kurano, Yutaka Yatomi
doaj   +1 more source

Novel Treatment Paradigms: Primary IgA Nephropathy

Kidney International Reports
IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Approximately 30% to 45% of patients progress to kidney failure (KF) within 20 to 25 years of diagnosis, and there has long been a lack of effective treatments.
Haresh Selvaskandan, Jonathan Barratt, Chee Kay Cheung   +2 more
doaj   +1 more source

Steroid therapy is effective for IgA nephropathy after liver transplantation in a pediatric patient

Clinical Case Reports, 2021
Hepatic IgA nephropathy is a complication of chronic liver disease. IgA nephropathy after liver transplantation is rare, especially in children, and carries a significant risk factor for chronic renal failure and mortality.
Hiroshi Tamura, Shohei Kuraoka, Hitoshi Nakazato   +2 more
doaj   +1 more source

Immunoglobulin A-nephropathy: modern view of the problem and treatment options

Лечащий Врач, 2021
The presented review discusses the mechanisms of development, the issues of diagnosis and the possibility of therapy for IgAnephropathy. IgA-nephropathy is an immunocomplex lesion of the glomeruli, characterized by the predominant deposition of ...
I. T. Murkamilov, I. S. Sabirov, V. V. Fomin, Zh. A. Murkamilova   +3 more
doaj   +1 more source

The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy

Frontiers in Immunology, 2019
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide and a common cause of end-stage renal disease. Evaluation of a kidney biopsy is necessary for diagnosis, with routine immunofluorescence microscopy revealing dominant ...
Dana V. Rizk, Nicolas Maillard, Bruce A. Julian, Barbora Knoppova, Barbora Knoppova, Todd J. Green, Jan Novak, Robert J. Wyatt   +7 more
doaj   +1 more source

Targeting GALNT7 Disrupts the TAZ O‐GalNAcylation Feedback Loop to Suppress Gallbladder Cancer Progression

Advanced Science, EarlyView.
Aberrant GALNT7‐mediated O‐GalNAcylation stabilizes TAZ to drive gallbladder cancer progression through a feed‐forward transcriptional loop. Structure‐based screening identifies Olaparib as a potent GALNT7 antagonist that disrupts this oncogenic axis, providing an immediate therapeutic strategy for this aggressive malignancy.
Peng Qiu, Ming Zhang, Yunxiang Feng, Yibo Deng, Kai Zhao, Xiangyu Li, Yun Lu, Li Tian, Tao Yang, Wei Yao, Jianming Wang, Zhengdong Deng   +11 more
wiley   +1 more source